Research Article
The Gut-Liver Axis in Nonalcoholic Fatty Liver Disease: Association of Intestinal Permeability with Disease Severity and Treatment Outcomes
Table 2
Comparison of clinical parameters in NAFLD patients with normal or elevated intestinal permeability.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
ALT, alanine transaminase; AST, aspartate transaminase; DAO, diamine oxidase; DBIL, direct bilirubin; FAP, fat attenuation parameter; GGT, gamma-glutamyl transpeptidase; HDL, high-density lipoprotein; HOMA-IR, homeostasis model assessment of insulin resistance; IBIL, indirect bilirubin; LDL, low-density lipoprotein; LPS, lipopolysaccharide; LSM, liver stiffness measurement; NAFLD, nonalcoholic fatty liver disease; TBIL, total bilirubin; TC, total cholesterol; TG, triglyceride. Normal intestinal permeability was defined as D-lactate<15 U/L, and elevated intestinal permeability was defined as D-lactate≥15 U/L. Significant P values are indicated in bold font. |